ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Acura Pharmaceuticals, Inc." (ACUR) Report Updated: Aug 22, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Acura Pharmaceuticals, Inc." (ACUR)

Rating: Strong Sell Volatility: Moderate
Total Grade: F Industry: Pharmaceuticals
Competitors: HSKA,JNJ,BPTH,SUPN

Stock Analysis

Rating: Monthly View

A
B
C
D
F
August September October November December January February March April May June July

Rating: Weekly View

This Week: F down downgrade
Last Week: D same upgrade
Two Weeks Ago: F up no change
service keys

"Acura Pharmaceuticals, Inc."© quotemedia

Company Profile

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, researches, develops, and commercializes products to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies. The company offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets for the use as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. It has seven additional opioid products, including hydrocodone bitartrate/acetaminophen, hydromorphone HCl, methadone HCl, morphine sulfate, oxycodone HCl/acetaminophen, oxymorphone HCl, and tramadol HCl tablets utilizing Aversion technology in various stages of development. The company has collaboration and license agreements with Egalet US, Inc.; Egalet Ltd.; and Egalet Corporation to manufacture and commercialize Oxaydo products worldwide. Acura Pharmaceuticals, Inc. was founded in 1935 and is based in Palatine, Illinois.